Biotech Stocks Move Higher: CGON +18%, CNSP +13%, LXEO +8%, XRTX +7%
CG Oncology (CGON) +18% after positive Phase 3 bladder cancer trial data. CNS Pharmaceuticals (CNSP) +13% on pipeline acquisition progress. Lexeo Therapeutics (LXEO) +8% with encouraging gene therapy results. XORTX Therapeutics (XRTX) +7% after completing clinical drug manufacturing for gout program.


